Colchicine Therapy

Primary Indications

The American College of Rheumatology recommends colchicine as the mainstay treatment for Familial Mediterranean Fever (FMF) and should be started as soon as a clinical diagnosis is made, with the ultimate goal of achieving complete control of unprovoked attacks and minimizing subclinical inflammation between attacks 1, 2
Colchicine prevents the development of AA amyloidosis, a serious complication that develops from ongoing uncontrolled inflammation, and should be continued during conception, pregnancy, and lactation without discontinuation 1, 2
For acute gout attacks, colchicine is a first-line agent with recommended dosing of 1.2 mg at the first sign of flare followed by 0.6 mg one hour later, providing 50% pain relief in approximately one in three patients (NNT = 3) 3, 4
In patients after acute coronary syndrome (ACS), low-dose colchicine may be reasonable to reduce risk of major adverse cardiovascular events (MACE), with the COLCOT trial showing a 32% reduction in the composite outcome of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent coronary revascularization 5

The recommended dose for cardiovascular disease is 0.5 to 0.6 mg daily 5
In patients with decreased renal function, the risk of toxicity is very high; monitor creatine phosphokinase (CPK) levels carefully and reduce dose accordingly 1, 2

Colchicine is contraindicated in patients with liver or kidney problems who are taking strong CYP3A4 and/or P-glycoprotein inhibitors, as this combination can be fatal 1, 6
High-risk interacting medications include macrolides, azole antifungals, HIV protease inhibitors, cyclosporine, verapamil, and statins 5, 6
Colchicine overdose can be fatal, with a narrow therapeutic index requiring careful monitoring, and toxicity manifests in three stages 1, 6

Response, toxicity, and compliance should be monitored every 6 months in stable FMF patients, with regular monitoring of complete blood counts and liver function tests 1, 2
In FMF, monitor inflammatory markers (SAA or CRP) at least every 3 months during dose escalation 2

Never discontinue colchicine during pregnancy or lactation in FMF patients, as current evidence does not justify amniocentesis or treatment cessation 1, 2
Do not use intravenous colchicine due to potential for severe and fatal toxicity 3

The European League Against Rheumatism recommends continuous daily use of colchicine in FMF, with treatment starting immediately upon clinical diagnosis and never being discontinued, at a dose of 1.2 to 2.4 mg daily for adults, adjusted in 0.3 mg increments based on response and tolerance 7
The dose can be given once daily or divided into two doses depending on gastrointestinal tolerance, with a maximum dose of 3 mg/day for adults 7

Regular visits every 3-6 months once stable, with more frequent monitoring during the first year or when adjusting doses, are recommended by the European League Against Rheumatism 8
Monitoring inflammatory markers (such as a similar protein to SAA or CRP) at least every 3 months during dose escalation is recommended 7

The European League Against Rheumatism warns that colchicine has a narrow therapeutic index, and toxicity risk increases dramatically with renal impairment, hepatic dysfunction, or concurrent use of CYP3A4/P-glycoprotein inhibitors 8
Significant dose reductions are required when coadministering colchicine with macrolides, azole antifungals, HIV protease inhibitors, cyclosporine, verapamil, and statins, which can increase colchicine blood levels by 200-300% 8